Basic information Safety Related Supplier
ChemicalBook >  Product Catalog >  Biochemical Engineering >  Inhibitors >  protein tyrosine kinase >  Palbociclib

Palbociclib

Basic information Safety Related Supplier
Palbociclib Basic information
Palbociclib Chemical Properties
  • Melting point:200 ºC
  • Boiling point:711.5±70.0 °C(Predicted)
  • Density 1.313±0.06 g/cm3(Predicted)
  • storage temp. room temp
  • pka8.66±0.10(Predicted)
  • form powder
  • color white to beige
Palbociclib Usage And Synthesis
  • DefinitionChEBI: A member of the class of pyridopyrimidines that is 2-{[5-(piperazin-1-yl)pyridin-2-yl]amino}pyrido[2,3-d]pyrimidin-7-one bearing additional methyl, acetyl and cyclopentyl substituents at positions 5, 6 and 8 respectively. It is used in combina ion with letrozole for the treatment of metastatic breast cancer.
  • IndicationsPalbociclib (Ibrane(R), Pfizer), a selective CDK4 and CDK6 inhibitor, received accelerated approval from FDA in 2015 for women with estrogen receptor-positive and HER2-negative breast cancer in combination with letrozole.
  • Enzyme inhibitorThis orally active, non-ATP-competitive cyclin kinase-directed inhibitor (FW = 483.99 g/mol (mono-HCl); CASs = 827022-32-2 (mono- hydrochloride, 571190-30-2 (free base); Solubility: 10 mg/mL DMSO; 30 mg/mL Water; Formulation: Dissolved in sodium lactate buffer (50 mM, ® pH 4.0) ), also known as PD-0332991, Ibrance, and 6-acetyl-8-cyclopentyl- 5-methyl-2- (5- (piperazin-1-yl) pyridin-2-ylamino) pyrido[2,3-d]pyrimidin- 7 (8H) -one hydrochloride, targets Cdk-4 (Cyclin D1) and Cdk-6 (Cyclin D2), enzymes that participate in the so-called CDK4/6-retinoblastoma signaling pathway governing the cell-cycle restriction point. Palbociclib induces rapid G1 cell-cycle arrest in primary human myeloma cells. This agent also shows significant efficacy in a broad spectrum of human tumor xenografts in vivo, resulting in complete regression in some tumors with no evidence of acquired resistance or ability to circumvent the growth inhibitory properties of this agent. Ibrance received FDA approval in 2015 for combined use with letrozole to treat postmenopausal women with estrogen receptor- positive, (HER2) -negative advanced breast cancer as an initial endocrine- based therapy for metastatic disease. Cyclin Target Selectivity: Cdk1 (weak, if any), Cdk2 (weak, if any), Cdk3 (weak, if any), Cdk4 (IC50 = 11 nM), Cdk5 (weak, if any), Cdk6 (IC50 = 16 nM), Cdk7 (weak, if any), Cdk8 (weak, if any), Cdk9 (weak, if any), Cdk10 (weak, if any).
Palbociclib(571190-30-2)Related Product Information
PalbociclibSupplierMore
  • Company Name:ShangHai Biochempartner Co.,Ltd Gold
  • Tel:15971444841 159-71444841-
  • Email:amber@biochempartner.net
  •  
  • Company Name:Jinan Yuantai Pharmaceutical Co.,Ltd Gold
  • Tel:18560053868 0531-69959492-
  • Email:42660257@qq.com
  •  
  • Company Name:Jinan Baozhao Pharmaceutical Technology Co., Ltd. Gold
  • Tel:0531-86397156
  • Email:baozhaopharm@163.com
  •  
  • Company Name:Chongqing Beisheng Pharmachem Co., Ltd. Gold
  • Tel:17338322789 +86-023-68265899
  • Email:583009952@qq.com
  •  
  • Company Name:Jinan Baizhou Biological Technology Co., Ltd. Gold
  • Tel:18615427082
  • Email:2823799053@qq.com
  •